These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 15825182)

  • 1. Functional analysis of p53 gene and the prognostic impact of dominant-negative p53 mutation in endometrial cancer.
    Sakuragi N; Watari H; Ebina Y; Yamamoto R; Steiner E; Koelbl H; Yano M; Tada M; Moriuchi T
    Int J Cancer; 2005 Sep; 116(4):514-9. PubMed ID: 15825182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer.
    Hassan NM; Tada M; Hamada J; Kashiwazaki H; Kameyama T; Akhter R; Yamazaki Y; Yano M; Inoue N; Moriuchi T
    Cancer Lett; 2008 Oct; 270(1):108-19. PubMed ID: 18555592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dominant-negative mutation of p53 tumor suppressor gene in endometrial carcinoma.
    Sakuragi N; Hirai A; Tada M; Yamada H; Yamamoto R; Fujimoto S; Moriuchi T
    Gynecol Oncol; 2001 Dec; 83(3):485-90. PubMed ID: 11733960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 expression as a prognostic indicator of 5-year survival in endometrial cancer.
    Geisler JP; Geisler HE; Wiemann MC; Zhou Z; Miller GA; Crabtree W
    Gynecol Oncol; 1999 Sep; 74(3):468-71. PubMed ID: 10479512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression and mutation of p53 in endometrial carcinoma.
    Kohler MF; Berchuck A; Davidoff AM; Humphrey PA; Dodge RK; Iglehart JD; Soper JT; Clarke-Pearson DL; Bast RC; Marks JR
    Cancer Res; 1992 Mar; 52(6):1622-7. PubMed ID: 1540970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 as a prognostic indicator in endometrial cancer.
    Geisler JP; Wiemann MC; Zhou Z; Miller GA; Geisler HE
    Gynecol Oncol; 1996 May; 61(2):245-8. PubMed ID: 8626141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients.
    Kihana T; Hamada K; Inoue Y; Yano N; Iketani H; Murao S; Ukita M; Matsuura S
    Cancer; 1995 Jul; 76(1):72-8. PubMed ID: 8630879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 alteration independently predicts poor outcomes in patients with endometrial cancer: a clinicopathologic study of 131 cases and literature review.
    Lee EJ; Kim TJ; Kim DS; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG
    Gynecol Oncol; 2010 Mar; 116(3):533-8. PubMed ID: 20006376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulated p21(WAF1) overexpression impacts survival of surgically resected esophageal squamous cell carcinoma patients.
    Goan YG; Hsu HK; Chang HC; Chou YP; Chiang KH; Cheng JT
    Ann Thorac Surg; 2005 Sep; 80(3):1007-16. PubMed ID: 16122475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma.
    Ito K; Sasano H; Matsunaga G; Sato S; Yajima A; Nasim S; Garret CT
    J Pathol; 1997 Nov; 183(3):318-24. PubMed ID: 9422988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiogenesis, p53, and bcl-2 expression as prognostic indicators in endometrial cancer: comparison with traditional clinicopathologic variables.
    Erdem O; Erdem M; Dursun A; Akyol G; Erdem A
    Int J Gynecol Pathol; 2003 Jul; 22(3):254-60. PubMed ID: 12819392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.
    Dong P; Tada M; Hamada J; Nakamura A; Moriuchi T; Sakuragi N
    Clin Exp Metastasis; 2007; 24(6):471-83. PubMed ID: 17636407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma.
    Ichikawa A; Kinoshita T; Watanabe T; Kato H; Nagai H; Tsushita K; Saito H; Hotta T
    N Engl J Med; 1997 Aug; 337(8):529-34. PubMed ID: 9262496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
    Alvarez T; Miller E; Duska L; Oliva E
    Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclooxygenase-2 and p53 expressions in endometrial cancer.
    Jeon YT; Kang S; Kang DH; Yoo KY; Park IA; Bang YJ; Kim JW; Park NH; Kang SB; Lee HP; Song YS
    Cancer Epidemiol Biomarkers Prev; 2004 Sep; 13(9):1538-42. PubMed ID: 15342458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
    Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
    Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 interference and growth inhibition in p53-mutant and overexpressing endometrial cancer cell lines.
    Janicek MF; Angioli R; Unal AD; Sevin BU; Madrigal M; Estape R; Averette HE
    Gynecol Oncol; 1997 Jul; 66(1):94-102. PubMed ID: 9234928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of p53/BAX in primary colorectal carcinoma: low BAX protein expression is a negative prognostic factor in UICC stage III tumors.
    Schelwies K; Sturm I; Grabowski P; Scherübl H; Schindler I; Hermann S; Stein H; Buhr HJ; Riecken EO; Zeitz M; Dörken B; Daniel PT
    Int J Cancer; 2002 Jun; 99(4):589-96. PubMed ID: 11992551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.